Sandbox:Usman Shah

Revision as of 17:09, 20 July 2020 by Usman Shah (talk | contribs)
Jump to navigation Jump to search

Covid-19 Associated ARDS

Overview


Historical Perspective

  • On 31 December 2019, the World Health Organization (WHO) was formally notified about a cluster of cases of pneumonia in Wuhan City.[1]
  • Ten days later, WHO was aware of 282 confirmed cases, of which four were in Japan, South Korea and Thailand
  • The virus responsible was isolated on 7 January and its genome shared on 12 January.The cause of the severe acute respiratory syndrome that became known as COVID‐19 was a novel coronavirus, SARS‐CoV‐2
  • ARDS is one of the most important causes of hospital and ICU admission due to COVID.
  • Many autopsies studies reported ARDS to be the cause of death in patients dying due to respiratory complications of COVID.
  • As of July 19 2020 the number of total cases worldwide are 14,043,176 including 597,583 deaths, reported to WHO.


Classification

Authors in a case report highlighted the nonuniformity of patients with COVID-19-associated ARDS and proposed the existence of two primary phenotypes:

ARDS is divided into three categories based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O:

  • mild (200 mmHg ≤ PaO2/FiO2 < 300 mmHg),
  • mild-moderate (100 mmHg ≤ PaO2/FiO2 < 200 mmHg), and
  • moderate-severe (PaO2/FiO2 < 100 mmHg).[3]


Pathophysiology


Covid19 healthcare worker. [1]


Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -

[7] [1]


Infra-Hisian Block Microchapters

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Treatment

Prevention

Differentiating Infra-Hisian Block from other Diseases




References

  1. 1.0 1.1 Chaplin, Steve (2020). "COVID ‐19: a brief history and treatments in development". Prescriber. 31 (5): 23–28. doi:10.1002/psb.1843. ISSN 0959-6682. line feed character in |title= at position 6 (help)
  2. Fan, Eddy; Beitler, Jeremy R; Brochard, Laurent; Calfee, Carolyn S; Ferguson, Niall D; Slutsky, Arthur S; Brodie, Daniel (2020). "COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?". The Lancet Respiratory Medicine. doi:10.1016/S2213-2600(20)30304-0. ISSN 2213-2600.
  3. Li, Xu; Ma, Xiaochun (2020). "Acute respiratory failure in COVID-19: is it "typical" ARDS?". Critical Care. 24 (1). doi:10.1186/s13054-020-02911-9. ISSN 1364-8535.
  4. "COVID-19 | Radiology Reference Article | Radiopaedia.org".
  5. Iannaccone, Giulia; Scacciavillani, Roberto; Del Buono, Marco Giuseppe; Camilli, Massimiliano; Ronco, Claudio; Lavie, Carl J.; Abbate, Antonio; Crea, Filippo; Massetti, Massimo; Aspromonte, Nadia (2020). "Weathering the Cytokine Storm in COVID-19: Therapeutic Implications". Cardiorenal Medicine: 1–11. doi:10.1159/000509483. ISSN 1664-3828.
  6. Meduri, G. Umberto; Annane, Djillali; Chrousos, George P.; Marik, Paul E.; Sinclair, Scott E. (2009). "Activation and Regulation of Systemic Inflammation in ARDS". Chest. 136 (6): 1631–1643. doi:10.1378/chest.08-2408. ISSN 0012-3692.
  7. Kiran U, Aggarwal S, Choudhary A, Uma B, Kapoor PM (2017). "The blalock and taussig shunt revisited". Ann Card Anaesth. 20 (3): 323–330. doi:10.4103/aca.ACA_80_17. PMC 5535574. PMID 28701598.